MHRA advises on anticoagulant dose adjustment in patients with renal impairment

Estimated glomerular filtration rate (eGFR) should not be used to adjust doses of direct-acting oral anticoagulants in patients with renal impairment, the MHRA has advised.

For most drugs and for most adult patients of average build and height, eGFR is an acceptable estimate of renal function.

However, use of eGFR to guide dosing of direct-acting oral anticoagulants is known to increase the risk of bleeding events as a consequence of overestimating renal function. In patients taking these drugs, the MHRA says creatinine clearance should be calculated using the Cockcroft-Gault formula to determine dosage adjustments.

Creatinine clearance should also be used to determine dosage adjustments for:

  • patients taking nephrotoxic drugs (such as vancomycin and amphotericin B)
  • elderly patients (aged 75 years and older)
  • patients at extremes of muscle mass (BMI < 18kg or > 40kg/m²)
  • patients taking medicines that are largely renally excreted and have a narrow therapeutic index (such as digoxin and sotalol)

Prescribers can quickly look up dose adjustments for direct-acting oral anticoagulants in renal impairment using the at-a-glance MIMS guide to NOAC dosages in non-valvular atrial fibrillation.

There are currently four direct-acting oral anticoagulants available in the UK: apixaban, dabigatran, edoxaban, and rivaroxaban.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)